Kornimate/medical-research-clean huggingface dataset:
abnormalities of the eye's anterior chamber, iris, cornea and lens

Conditions: Aniridia; Eye Abnormality; Ocular Hypertension; Open Angle Glaucoma

Summary: this study will investigate congenital or developmental eye abnormalities that affect the iris, cornea and lens, and are usually accompanied by elevated pressure within the eye. these disorders can cause vision loss, and the increased eye pressure can lead to glaucoma, a condition that may also cause loss of eyesight. patients with eye anterior chamber eye disease, such as axenfeld's syndrome, rieger's anomaly, peter's anomaly, iridocorneal endothelial syndrome, megalocornea, ocular hypertension, and others, are eligible for this study. participants will have a medical examination, family history, and comprehensive eye examination. tests and procedures may include photographs of the cornea, iris, and the structure through which fluid that normally circulates behind the cornea drains out of the eye. some patients may undergo indentation tonography to measure how easily this fluid drains. in this procedure, the patient lies on an examination table and both eyes are numbed with eye drops. a small instrument (tonometer) is placed on the surface of one eye, and with the other eye, the patient looks at an overhead light. other tests may include photographs of the back of the eye and ultrasound imaging of the structures of the eye. a blood sample may be drawn to study the genetic disorder responsible for the disease. patients will have follow-up examinations every 6 months for the duration of the study. medical or surgical therapy will be recommended, as appropriate, for patients who develop elevated eye pressure or vision loss.

this study will concentrate on abnormalities of the anterior chamber with or without elevated intraocular pressure. the purpose of the study will be to determine if there is a common pathogenesis shared by these conditions. a natural history study of 40 individuals with these diseases will utilize clinical measurements and photographs for documentation of this hypothesis. in addition, surgical specimens, when available, will be studied.

Eligibility criteria:
the eye conditions to be studied include axenfeld's syndrome, rieger's anomaly, peter's anomaly, (all with or without glaucoma), iridocorneal endothelial syndrome, aniridia, pigment dispersion syndrome, megalocornea and other conditions with clinical abnormalities of the anterior chamber. patients will not be included in the study if they do not fit the morphologic characteristics of the disease in question or if the patient's general medical condition or other related factors make it impossible for him or her to continue participation in the study.

Keywords: irido corneal angle mesothelium congenital anomalies neural crest increased intraocular pressure glaucoma axenfeld's syndrome rieger's anomaly peter's anomaly iridocorneal endothelial syndrome aniridia pigment dispersion syndrome megalocornea
correlation between functional capacity and functional capability in duchenne muscular dystrophy

Conditions: Duchenne Muscular Dystrophy

Summary: this study investigates the correlation between assessments measuring functional capacity and functional capability in patients with duchenne muscular dystrophy.

this study is a prospective single-arm observational study, with a total of two visits for one year follow-up.

Eligibility criteria:
inclusion criteria: 1. children aged 5 to 18 years diagnosed with duchenne muscular dystrophy through genetic testing 2. children who understand the contents of this research and can properly conduct the research exclusion criteria: 1. requiring daytime ventilator assistance or using invasive mechanical ventilation through tracheostomy (non-invasive mechanical ventilation such as positive pressure ventilation at night is allowed) 2. history of peripheral nerve damage 3. history of major surgery within 12 weeks or if major surgery is expected during the test period 4. history of central nervous system disorders (eg, cerebral infarction, spinal cord injury) 5. having difficulties in conducting this study due to cognitive decline.

Keywords: duchenne muscular dystrophy dmd accelerometer actigraph dexa muscle ultrasound
effect of alpha-lipoic acid on biochemical markers and important outcomes in patients admitted to intensive care units

Conditions: Oxidative Stress; Inflammation; Malnutrition

Summary: increasing reactive oxygen and nitrogen production occurred simultaneously with decreasing serum and intracellular level of antioxidants and enzymes in critical ill patients, which result in increasing ventilator dependency and length of stay in intensive care unit and it also accelerate organ failures in patients. in this double blind clinical trial, the investigators examine effect of alfa-lipoic acid on those patients who admitted to intensive care unit that the investigators expect to stay for more than 7 days in this ward and who have tube feeding and don't have severe liver and kidney failure, aids and hepatitis. after randomization of included patients by block randomization the investigators will give 900mg/day alfa-lipoic acid for ten days to treatment group and identical placebo to control group by naso-gastric tube. the purposes of this study are decreasing ventilator dependency period, length of stay in icu, mortality and decelerate of organ failures.


Eligibility criteria:
inclusion criteria: * age ≥ 18; * expected length of stay more than 7 days; * using enteral feeding method during admitted to icu exclusion criteria: * having the history of autoimmune disease * severe renal or liver failure * aids, * hepatitis; * having severe malnutrition at the admission time; * having tpn at the admission time in icu; * extreme intolerance to enteral feeding.

Keywords: length of stay in icu ventilator free days
therapeutic targeting of sex differences in pediatric brain tumor glycolysis

Conditions: Pediatric Brain Tumor

Summary: the investigators will develop the concept of a sex-specific therapeutic intervention for gliomas that is based upon dietary carbohydrate restriction. the investigators will integrate metabolomics tools and fdg-pet imaging to validate the ketogenic diet on a sex-specific basis.


Eligibility criteria:
inclusion criteria: * diagnosis of a recurrent primary brain tumor with no curative therapy available. * measurable disease using pediatric response assessment in neuro-oncology criteria (rano) criteria. * life expectancy \> 12 weeks * prior treatment with radiation alone, chemotherapy alone or combined radiation and chemotherapy is allowed. * patient is \< 21 years of age * normal bone marrow and organ function as defined below: * leukocytes ≥ 3,000/mcl * absolute neutrophil count ≥ 1,500/mcl * platelets ≥ 100,000/mcl * total bilirubin ≤ 1.5 x iuln * ast(sgot)/alt(sgpt) ≤ 3.0 x iuln * creatinine ≤ iuln or creatinine clearance ≥ 60 ml/min/1.73 m2 for patients with creatinine levels above institutional normal * normal room air oxygenation must be documented. if room air oxygen saturation is less than 97%, a diffusion capacity of carbon monoxide (dlco) of greater than 80%, must be demonstrated. * karnofsky or lansky performance score of ≥ 60 * patients of childbearing potential must agree to use adequate contraception (hormonal or barrier method of birth control, abstinence) prior to study entry and for the duration of study participation. should a female patient become pregnant or suspect she is pregnant while participating in this study, she must inform her treating physician immediately. * ability to understand and willingness to sign an irb approved written informed consent document (or that of legally authorized representative, if applicable). exclusion criteria: * patient does not have any of the following conditions as they are contraindicated for ketogenic diet: * primary and secondary carnitine deficiency * carnitine palmitoyltransferase i or ii deficiency * carnitine translocase deficiency * mitochondrial β-oxidation defects * pyruvate carboxylase deficiency * glycogen storage diseases * ketolysis defects * ketogenesis defects * porphyria * prolonged qt syndrome * liver insufficiency * renal insufficiency * pancreatic insufficiency * pulmonary insufficiency * hyper insulinism * pregnant and/or breastfeeding. female patients of childbearing potential must have a negative pregnancy test within 14 days of study entry.
efficacy of nalmefene in patients with alcohol dependence

Conditions: Alcohol Dependence

Summary: the purpose of the study is to evaluate the efficacy, safety and tolerability of nalmefene in the treatment of alcohol dependence.

alcohol dependence is a maladaptive pattern of alcohol use, leading to clinically significant impairment or distress, as manifested by at least three of a number of criteria such as tolerance, withdrawal symptoms, frequent use of alcohol in larger amounts or over longer periods than was intended, and others. excessive intake of alcohol reduces the life span by a decade, and alcohol drinking is strongly related to mortality from liver cirrhosis, chronic pancreatitis, certain cancers, hypertension, accidents and violence. this study is planned to evaluate the efficacy and safety of as needed use of nalmefene 18.06 mg versus placebo in decreasing monthly heavy drinking days (hdds) and decreasing the total consumption during a period of 24 weeks in adult patients with alcohol dependence.

Eligibility criteria:
inclusion criteria: in- and outpatients who: * had a primary diagnosis of alcohol dependence according to diagnostic and statistical manual of mental disorders - text revision (dsm-iv-tr) criteria * had had ≥6 hdds in the 4 weeks preceding the screening visit * had had an average alcohol consumption at who medium risk level or above in the 4 weeks preceding the screening visit exclusion criteria: the patient: * had a dsm-iv axis i disorder other than alcohol dependence or nicotine dependence * had an antisocial personality disorder * had risk of suicide evaluated by the suicidality module of the mini-international neuropsychiatric interview (mini) * had a history of delirium tremens or alcohol withdrawal seizures * reported current or recent (within 3 months preceding screening) treatment with disulfiram, acamprosate, topiramate, naltrexone or carbimide, or with any opioid antagonists * reported current or recent treatment with antipsychotics or antidepressants * was pregnant or breast-feeding other protocol-defined inclusion and exclusion criteria may apply.

Keywords: pharmacologic actions alcohol-related disorders alcoholism mental disorders central nervous system agents
sirolimus-eluting versus paclitaxel-eluting stents for coronary revascularization

Conditions: Coronary Heart Disease

Summary: context: sirolimus-eluting stents and paclitaxel-eluting stents, as compared with bare-metal stents, reduce the risk of restenosis. it is unclear whether there are differences in safety and efficacy between the two types of drug-eluting stents. objective: to determine differences in safety and efficacy between sirolimus and paclitaxel eluting stents.

design: randomized controlled, observer-blind trial comparing sirolimus-eluting stents with paclitaxel-eluting stents patients: 1012 patients undergoing percutaneous coronary intervention. the two groups had similar baseline clinical and angiographic characteristics.

Eligibility criteria:
inclusion criteria: patients with either stable angina or an acute coronary syndrome were eligible to participate if they had at least one lesion with stenosis of at least 50 percent in a vessel with a reference diameter between 2.25 and 4.00 mm that was suitable for stent implantation. exclusion criteria: allergy to antiplatelet drugs, heparin, stainless steel, contrast agents, sirolimus, or paclitaxel; participation in another coronary-device study; and terminal illness.

Keywords: coronary revascularization sirolimus-eluting stents paclitaxel-eluting stents
use of cog by patients with diabetes mellitus

Conditions: Diabetes Mellitus

Summary: the cnoga combo glucometer (cog) employs an invasive glucose meter using blood glucose teststrips and requiering a capillary blood sample obtained from a fingerstick and in addition, a non-invasive optical component for prediction of tissue glucose at the fingertip. in this study, participants will use both devices during meal tests and also at home during routine care. the results from the device will be compared to a standard reference method and will be used to determine the accuracy of the two device components.

the trial starts with a screening and training visit (v1). this is followed by an individual calibration period for the non-invasive device component by means of multiple parallel measurements with the invasive and the noninvasive device component. this will be done by the participants at home. thereafter, the participants will come to the study site and will ingest a standardized meal (v2). blood will be drawn for assessment of hba1c and biochemical safety parameters. during the next 3 hours, 11 fingersticks will be made to obtain capillary blood samples for comparator readings with the two cog components and with a laboratory reference method (ysi gucose analyzer). the patients will now continue to use the devices at home for three months, but are not allowed to use any cog result for treatment decisions. in an interim visit after 6 weeks (v3), blood will be drawrn for hba1c and biochemical safety parameters and three comparison measurements will be made with the cog device components and the laboratory reference method. at the final visit after 12 weeks (v4), the procedures of the first meal test visit (v2) will be repeated, which conludes that study. in addition, the participants will be asked to complete a device satisfaction questionnaire at v2, v3, and v4.

Eligibility criteria:
inclusion criteria: * patients with type 1 or type 2 diabetes of afro-american, hispanic, or asian-american origin * subjects who are able to provide informed consent (by him/herself or by his/her guardian); * 18 years old and above; * hba1c \< 10 % * anatomically suitable finger as determined by the clinical investigator and detailed in section 4 exclusion criteria: * does not meet inclusion criteria; * subjects requiring dialysis; * any conditions that may hamper good visual contact between the finger and sensor, such as raised birthmarks, scars and/or tattoos; * pregnancy; * nursing mothers; * any skin injuries on the measured finger; * severe disease conditions (cancer etc.) * any condition that may prevent patients from successful participation in the trial (in discretion of the investigator)

Keywords: diabetes mellitus type 1 diabetes mellitus type 2 blood glucose self-testing non-invasive tissue glucose prediction optical pain-free glucose testing
chemotherapy and radiation therapy in treating patients with hiv-related primary central nervous system lymphoma

Conditions: Lymphoma

Summary: rationale: drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. combining radiation therapy with chemotherapy may kill more tumor cells. purpose: this phase ii trial is studying how well giving methotrexate and zidovudine together with radiation therapy works in treating patients with hiv-related primary central nervous system lymphoma.

objectives: * determine the efficacy of neoadjuvant chemotherapy and radiation therapy in the treatment of hiv-related primary cns lymphoma patients. * evaluate the toxicity and overall survival of these patients. outline: patients receive chemotherapy consisting of high-dose methotrexate iv administered on day 1 and high-dose zidovudine iv administered on days 1-3 every 2 weeks. patients receive 3 courses of therapy. following chemotherapy, patients receive radiation therapy to the lesion site daily. patients are followed every 3 months for 1 year and then every 6 months thereafter. projected accrual: this study will accrue 14 patients.

Eligibility criteria:
disease characteristics: * histologically proven hiv-related non-hodgkin's lymphoma of the cns * no systemic lymphoma patient characteristics: age: * 18 and over performance status: * who 0-3 life expectancy: * not specified hematopoietic: * wbc at least 3000/mm\^3 * platelet count at least 80,000/mm\^3 hepatic: * no serious impairment of liver function renal: * no serious impairment of renal function * creatinine clearance at least 40 ml/min cardiovascular: * no serious impairment of cardiac function neurologic: * neurological functional status 0-3 other: * no prior or active cns-opportunistic infections * no aids dementia complex * no active systemic infections prior concurrent therapy: * no prior chemotherapy or radiotherapy

Keywords: aids-related primary cns lymphoma
phase iii clinical trial to evaluate the efficacy and safety of dp-r208 and each monotherapy

Conditions: Hypertension; Cholesterolemia

Summary: the purpose of this study is to determine superiority of dp-r208 compare to each monotherapy in patient with hypertension and primary hypercholesterolemia.


Eligibility criteria:
inclusion criteria: * both man and woman who is over 19years old. * hypertension with primary cholesterolemia and satisfy the lab results that mean mssbp is under 180mmhg and mean msdbp is under 110mmhg and ldl-c is 250mg/dl or under and triglycerides is under 400mg/dl exclusion criteria: * therapeutic lifestylechange is not enought during the study period * sbp difference is bigger than 20mmhg or dbp difference is bigger than 10mmhg at screening visit

Keywords: dp-r208
a cluster-randomized cross-over trial evaluating the comparative effectiveness of three skin antiseptic interventions

Conditions: Bacteremia

Summary: background: contaminated blood cultures result in unnecessary antibiotic use, increased length of stay, and additional laboratory tests, all of which increase healthcare costs. while the optimal skin antisepsis agent for reducing blood culture contamination is not known, the cost of various agents differs substantially. objective: to determine the relative rates of blood culture contamination for 3 skin antisepsis interventions - 10% povidone iodine aqueous solution (pi), 2% iodine tincture (it) and 2% chlorhexidine gluconate in 70% isopropyl alcohol (chg) - when used by dedicated phlebotomy teams to obtain peripheral blood cultures in adult non-icu medical and surgical patients.

a group-randomized crossover trial was conducted to test the null hypothesis of no difference in blood culture contamination rates among 3 antiseptic skin preparations. the sequence of 3 different antiseptic treatments was randomly assigned to 3 separate hospital floors, therefore in this trial cross-over occurred at the hospital floor level (not the individual patient level). also, it is possible for subjects to have multiple blood culture sets obtained during the study. thus, the number of blood culture sets will not equal the number of unique subjects in the study.

Eligibility criteria:
inclusion criteria: * patient on general medical, surgical, and cardiology floors * receipt of a peripheral blood draw for blood culture collection * blood draw performed by phlebotomy team exclusion criteria: * none

Keywords: bacteremia blood culture contamination antiseptic agents
efficacy of propolis in the prevention of oral mucositis

Conditions: Oral Mucositis

Summary: the study was carried out to determine the efficacy of propolis in the prevention of oral mucositis and gastrointestinal symptoms associated with oral mucositis in patients with leukemia, lymphoma, and myelodysplastic syndrome receiving high-dose chemotherapy and/or hematopoietic stem cell transplantation. 64 patients, 32 in the propolis and 32 in the control group, were involved in the prospective randomized controlled experimental study. while the standard oral care treatment protocol of the clinic was administered to the control group, aqueous propolis extract was applied to the propolis group in addition to the standard oral care treatment protocol.

objective: the study was carried out to determine the efficacy of propolis in the prevention of oral mucositis and gastrointestinal symptoms associated with oral mucositis in patients with leukemia, lymphoma, and myelodysplastic syndrome receiving high-dose chemotherapy and/or hematopoietic stem cell transplantation. study design: the study was conducted as a randomized controlled experimental study. approval from the ethics committee and written permission from the institution were obtained. after the participants were informed about the purpose of the study, their written consents were obtained. 64 patients, 32 in the propolis and 32 in the control group were involved in the study that was performed in the hematology and bone marrow transplantation unit. the control group patients used the standard oral care treatment protocol (tanflex (3x1) and nahco3 (1x1)) of the clinic , while the propolis group used the aqueous extract of propolis in addition to this protocol. the individuals in the propolis group gargled 4 times a day (after meals and before going to bed at night) with 5 ml aqueous propolis extract. all patients underwent a daily intraoral examination up to 21 days from the start of high dose chemotherapy. oral mucositis was recorded on the who oral toxicity scale and other gastrointestinal symptoms were recorded on the national cancer institute-common terminology criteria for adverse events scale

Eligibility criteria:
inclusion criteria: * 18 years or older * ability to communicate verbally * not having a diagnosed psychiatric disease * receiving inpatient high dose chemotherapy (diagnosed with leukemia, lymphoma and mds) * hematopoietic stem cell transplantation patients * zero om score according to the world health organization oral toxicity scale (whoots) * karnofsky performance scale (kps) score of 80 and above exclusion criteria: -

Keywords: oral mucositis propolis high dose chemotherapy
mapracorat ophthalmic suspension, 3% for the treatment of ocular inflammation and pain following cataract surgery

Conditions: Cataract; Inflammation; Surgery

Summary: the objective of this clinical study is to compare the safety and efficacy of mapracorat ophthalmic suspension, 3% with its vehicle for the treatment of postoperative inflammation and pain following cataract surgery.


Eligibility criteria:
inclusion criteria: * subjects who are candidates for routine, uncomplicated cataract surgery. * subjects who, in the investigator's opinion, have potential postoperative pinhole snellen visual acuity (va) of at least 20/200 in the study eye. * subjects who have ≥ grade 2 (6 - 15 cells) ac cells in the study eye following cataract surgery (postoperative day 1). exclusion criteria: * subjects who have a severe/serious ocular condition or history/presence of chronic generalized systemic disease that the investigator feels might increase the risk to the subject or confound the result(s) of the study. * any intraocular inflammation in either eye (cells or flare score greater than grade 0 at slit lamp examination) or ocular pain greater than grade 1 in the study eye at the screening visit. * presence of active external ocular disease: infection or inflammation of the study eye. * subjects who have known hypersensitivity or contraindication to the study drug(s) or their components. * subjects who currently require or are expected to require treatment with any medication listed as a disallowed medication per the disallowed therapy section of the protocol.
study of ins365 ophthalmic solution in a controlled adverse environment in patients with dry eye

Conditions: Keratoconjunctivitis Sicca

Summary: comparative efficacy trial of ins365 ophthalmic solution and placebo in patients with dry eye.


Eligibility criteria:
inclusion criteria: * have non-sjogren's associated dry eye disease with symptoms lasting greater than 6 months * had intermittent or regular artificial tear use within past 3 months exclusion criteria: * had lasik surgery * had punctal occlusion or cauterization within last 3 months

Keywords: dry eye